PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.74%
Both yoy net incomes decline, with CRVO at -118.64%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-40.21%
Negative yoy D&A while CRVO is 142.10%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
147.42%
Deferred tax of 147.42% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-33.50%
Negative yoy SBC while CRVO is 240.31%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2171.95%
Slight usage while CRVO is negative at -78.41%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
577.15%
A yoy AP increase while CRVO is negative at -460.81%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-447.03%
Negative yoy usage while CRVO is 44326.33%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-33.50%
Both negative yoy, with CRVO at -100.00%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-13.29%
Both yoy CFO lines are negative, with CRVO at -162.24%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
19.79%
Lower CapEx growth vs. CRVO's 100.00%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.79%
Lower net investing outflow yoy vs. CRVO's 100.00%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
-207.32%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
104.75%
Issuance growth of 104.75% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.